IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
IN8bio, Inc. (INAB)
Company Research
Source: GlobeNewswire
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360° (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA. William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, “Tackling the Tough Questions in IO for Autoimmunity Disease.” After, he will Chair the session, “State of the IO Market, Investments and Deals Plenary.” During the afternoon se
Read more
Impact Snapshot
Event Time:
INAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INAB alerts
High impacting IN8bio, Inc. news events
Weekly update
A roundup of the hottest topics
INAB
News
- IN8bio to Present New Preclinical Data on Novel Gamma-Delta (?d) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025GlobeNewswire
- IN8bio, Inc. (NASDAQ: INAB) had its price target lowered by analysts at HC Wainwright from $8.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- IN8bio Announces Advanced Gamma-Delta (?d) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases [Yahoo! Finance]Yahoo! Finance
- IN8bio Announces Advanced Gamma-Delta (?d) T cell Engager (TCE) Platform for Oncology and Autoimmune DiseasesGlobeNewswire
INAB
Earnings
- 3/13/25 - Miss
INAB
Analyst Actions
- 2/12/25 - HC Wainwright
INAB
Sec Filings
- 3/17/25 - Form ARS
- 3/17/25 - Form DEFA14A
- 3/17/25 - Form DEF
- INAB's page on the SEC website